As of Feb 03, 2025, Amgen Inc.'s Discounted Cash Flow (DCF) valuation estimates its share price at $539.3. This suggests it may be undervalued by 86.7% compared to its current price of around $288.9, using a WACC of 5.9% and growth rates of 3.0%.
As of Feb 03, 2025, Amgen Inc.'s Weighted Average Cost of Capital (WACC) is approximately 5.9%.
As of Feb 03, 2025, Amgen Inc.'s Enterprise Value (EV) is approximately $333.0B. This value reflects the company's total market capitalization plus debt, minus cash and cash equivalents, providing a comprehensive measure of its overall value in the market.